PT3127553T - Conjugados de derivado da caliqueamicina - transportador - Google Patents

Conjugados de derivado da caliqueamicina - transportador

Info

Publication number: PT3127553T
Authority: PT; Portugal
Prior art keywords: caliqueamicin; carrier; derivative conjugates; conjugates; derivative
Prior art date: 2002-05-02

Application number

PT161807292T

Other languages

English (en)

Portuguese (pt)

Original Assignee

Wyeth Holdings Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-02

Filing date

2003-05-02

Publication date

2022-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3127553(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-02 Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc

2022-01-24 Publication of PT3127553T publication Critical patent/PT3127553T/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Plant Pathology (AREA)

PT161807292T 2002-05-02 2003-05-02 Conjugados de derivado da caliqueamicina - transportador PT3127553T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37744002P	2002-05-02	2002-05-02

Publications (1)

Publication Number	Publication Date
PT3127553T true PT3127553T (pt)	2022-01-24

Family

ID=29401497

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT161807292T PT3127553T (pt)	2002-05-02	2003-05-02	Conjugados de derivado da caliqueamicina - transportador
PT37244324T PT1507556T (pt)	2002-05-02	2003-05-02	Conjugados de derivado da caliqueamicina - transportador
PT111579819T PT2371392E (pt)	2002-05-02	2003-05-02	Conjugados de derivado da caliqueamicina - transportador

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PT37244324T PT1507556T (pt)	2002-05-02	2003-05-02	Conjugados de derivado da caliqueamicina - transportador
PT111579819T PT2371392E (pt)	2002-05-02	2003-05-02	Conjugados de derivado da caliqueamicina - transportador

Country Status (33)

Country	Link
US (6)	US8153768B2 (2)
EP (3)	EP1507556B1 (2)
JP (5)	JP5153057B2 (2)
KR (2)	KR101125524B1 (2)
CN (1)	CN100482277C (2)
AU (2)	AU2003231293A1 (2)
BE (1)	BE2017C049I2 (2)
BR (3)	BR122019027966B8 (2)
CA (2)	CA2483552A1 (2)
CR (3)	CR7557A (2)
CY (4)	CY1116634T1 (2)
DK (3)	DK3127553T3 (2)
EC (1)	ECSP045445A (2)
ES (3)	ES2916174T3 (2)
FR (1)	FR17C1054I2 (2)
HU (4)	HUE030806T2 (2)
IL (2)	IL164946A (2)
LT (3)	LT3127553T (2)
LU (1)	LUC00044I2 (2)
MX (1)	MXPA04010792A (2)
NL (1)	NL300903I2 (2)
NO (3)	NO339730B1 (2)
NZ (2)	NZ573563A (2)
PH (2)	PH12013501158A1 (2)
PL (5)	PL224150B1 (2)
PT (3)	PT3127553T (2)
RU (3)	RU2422157C3 (2)
SG (3)	SG187991A1 (2)
SI (3)	SI2371392T1 (2)
TW (2)	TWI379693B (2)
UA (1)	UA88599C2 (2)
WO (1)	WO2003092623A2 (2)
ZA (2)	ZA200409752B (2)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6905669B2 (en)	2001-04-24	2005-06-14	Supergen, Inc.	Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20110045005A1 (en) *	2001-10-19	2011-02-24	Craig Crowley	Compositions and methods for the treatment of tumor of hematopoietic origin
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
SG187991A1 (en)	2002-05-02	2013-03-28	Wyeth Corp	Calicheamicin derivative-carrier conjugates
AR048098A1 (es) *	2004-03-15	2006-03-29	Wyeth Corp	Conjugados de caliqueamicina
WO2005115141A1 (ja) *	2004-05-26	2005-12-08	National University Corporation Kagawa University	希少糖を利用した細胞・組織・臓器保存液及び該液を用いる保存方法
TW200621282A (en) *	2004-08-13	2006-07-01	Wyeth Corp	Stabilizing formulations
US7335491B2 (en)	2004-08-27	2008-02-26	Wyeth Research Ireland Limited	Production of anti-abeta
TWI364458B (en)	2004-08-27	2012-05-21	Wyeth Res Ireland Ltd	Production of tnfr-lg
TWI384069B (zh)	2004-08-27	2013-02-01	Pfizer Ireland Pharmaceuticals	多胜肽之製法
CA2486285C (en) *	2004-08-30	2017-03-07	Viktor S. Goldmakher	Immunoconjugates targeting syndecan-1 expressing cells and use thereof
SV2007002227A (es) *	2004-09-10	2007-03-20	Wyeth Corp	Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
EP1661584A1 (en) *	2004-11-26	2006-05-31	Heinz Dr. Faulstich	Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
US20110166319A1 (en) *	2005-02-11	2011-07-07	Immunogen, Inc.	Process for preparing purified drug conjugates
US7250416B2 (en)	2005-03-11	2007-07-31	Supergen, Inc.	Azacytosine analogs and derivatives
US20070003559A1 (en) *	2005-07-01	2007-01-04	Wyeth	Methods of determining pharmacokinetics of targeted therapies
US7678832B2 (en)	2005-08-16	2010-03-16	Synta Pharmaceuticals Corp.	Bis(thio-hydrazide amide) formulation
CA3000520C (en)	2005-08-24	2023-04-04	Immunogen, Inc.	Process for preparing antibody maytansinoid conjugates
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2631714C (en)	2005-12-02	2014-09-16	Novartis Ag	Nanoparticles for use in immunogenic compositions
EP1957097A1 (en) *	2005-12-06	2008-08-20	Wyeth a Corporation of the State of Delaware	Interleukin-11 compositions and methods of use
DK2368914T3 (en)	2006-03-10	2019-03-04	Wyeth Llc	Anti-5T4 antibodies and uses thereof
ES2371085T3 (es) *	2006-05-27	2011-12-27	Faulstich, Heinz, Dr.	Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
EP3255141B1 (en)	2006-07-13	2021-12-01	Wyeth LLC	Production of antibodies with improved glycosylation pattern
RU2475478C2 (ru)	2006-08-21	2013-02-20	Синта Фармасьютиклз Корп.	Соединения для лечения пролиферативных расстройств
EP2076287A2 (en) *	2006-10-12	2009-07-08	Wyeth	Methods and compositions with reduced opalescence
ES2541546T3 (es)	2006-11-03	2015-07-21	Wyeth Llc	Sustancias que inhiben la glucólisis en cultivo celular
US8481683B2 (en)	2006-12-01	2013-07-09	Medarex, Inc.	Human antibodies that bind CD22 and uses thereof
EP2117601A2 (en) *	2006-12-22	2009-11-18	The Regents of the University of California	Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
EP2121750A2 (en) *	2007-01-16	2009-11-25	Wyeth	Inflammation treatment, detection and monitoring via trem-1
AU2008223133A1 (en)	2007-03-02	2008-09-12	Wyeth	Use of copper and glutamate in cell culture for production of polypeptides
KR101547705B1 (ko) *	2007-05-22	2015-08-26	와이어쓰 엘엘씨	히드라지드의 개선된 제조 방법
PE20090309A1 (es) *	2007-06-04	2009-04-18	Wyeth Corp	Conjugado portador-caliqueamicina y un metodo de deteccion de caliqueamicina
DK2211904T3 (en) *	2007-10-19	2016-10-24	Seattle Genetics Inc	Cd19-binding agents and uses thereof
WO2009086072A2 (en) *	2007-12-21	2009-07-09	Genentech, Inc.	Therapy of rituximab-refractory rheumatoid arthritis patients
WO2009080832A1 (en) *	2007-12-26	2009-07-02	Biotest Ag	Methods and agents for improving targeting of cd138 expressing tumor cells
CN101965366B (zh) *	2007-12-26	2016-04-27	生物测试股份公司	靶向cd138的免疫缀合物及其应用
US9221914B2 (en)	2007-12-26	2015-12-29	Biotest Ag	Agents targeting CD138 and uses thereof
WO2009080831A1 (en) *	2007-12-26	2009-07-02	Biotest Ag	Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
US20090186026A1 (en) *	2008-01-18	2009-07-23	Wyeth	Ephrin and eph receptor agonists for modulation of bone formation and resorption
WO2009124109A1 (en)	2008-04-04	2009-10-08	The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services	Human monoclonal antibodies specific for cd22
FR2930443B1 (fr)	2008-04-29	2010-06-25	Oreal	Produit extemporane de soin a base d'un lyophilisat de microorganisme et de tensioactif(s) de hlb superieur ou egal a 12
NZ610239A (en) *	2008-04-30	2014-11-28	Immunogen Inc	Cross-linkers and their uses
SG10201810743WA (en)	2009-06-03	2018-12-28	Immunogen Inc	Conjugation methods
EP2533814A2 (en) *	2010-02-11	2012-12-19	Ablynx N.V.	Delivery of immunoglobulin variable domains and constructs thereof
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
JP2013535981A (ja)	2010-08-20	2013-09-19	ワイス・エルエルシー	成長因子不含適合細胞の細胞培養
EP2625189B1 (en)	2010-10-01	2018-06-27	ModernaTX, Inc.	Engineered nucleic acids and methods of use thereof
EP2637692A4 (en)	2010-11-12	2014-09-10	Scott & White Healthcare	ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
US8512679B2 (en) *	2011-03-04	2013-08-20	Elwha Llc	Glassy compositions
ME03353B (me)	2011-03-29	2019-10-20	Immunogen Inc	Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
EP3431142B1 (en)	2011-08-30	2020-06-17	Astex Pharmaceuticals, Inc.	Decitabine derivative formulations
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
DE19216461T1 (de)	2011-10-03	2021-10-07	Modernatx, Inc.	Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
RU2663794C2 (ru)	2011-10-21	2018-08-09	Пфайзер Инк.	Добавление железа для улучшения культивирования клеток
KR20140100571A (ko)	2011-12-08	2014-08-14	바이오테스트 아게	Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
SG10201708959WA (en)	2012-07-03	2017-11-29	Univ Washington	Antibodies to tau
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
RU2661083C2 (ru)	2012-10-04	2018-07-11	Иммуноджен, Инк.	Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
CA2891280C (en)	2012-11-24	2018-03-20	Hangzhou Dac Biotech Co., Ltd.	Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
US9089614B2 (en)	2012-12-21	2015-07-28	Bioalliance C.V.	Hydrophilic self-immolative linkers and conjugates thereof
WO2014113203A1 (en)	2013-01-17	2014-07-24	Case Western Reserve University	Viral nanoparticle multimers
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
BR112015027474A8 (pt) *	2013-05-02	2018-01-23	Hoffmann La Roche	anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
JP2016540826A (ja)	2013-11-04	2016-12-28	ファイザー・インク	抗ｅｆｎａ４抗体−薬物コンジュゲート
CN108047287B (zh) *	2013-11-04	2021-04-27	辉瑞大药厂	用于合成加利车霉素衍生物的中间体和方法
US10464955B2 (en)	2014-02-28	2019-11-05	Hangzhou Dac Biotech Co., Ltd.	Charged linkers and their uses for conjugation
US10544395B2 (en)	2014-03-19	2020-01-28	Pfizer Inc.	Method of cell culture
US11998594B2 (en)	2014-04-02	2024-06-04	Case Western Reserve University	Anti-cancer plant virus particles linked to HER2 antigens
US9950077B2 (en)	2014-06-20	2018-04-24	Bioalliance C.V.	Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
TWI734975B (zh)	2014-06-27	2021-08-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗-tau抗體
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
US9925281B2 (en)	2014-08-05	2018-03-27	Case Western Reserve University	Coated plant virus imaging agents
US12465624B2 (en)	2018-05-08	2025-11-11	Case Western Reserve University	Cancer immunotherapy using virus particles and immune checkpoint therapy
EP3215520B1 (en)	2014-11-07	2022-01-05	Case Western Reserve University	Cancer immunotherapy using virus particles
JP6869187B2 (ja)	2015-04-07	2021-05-12	メモリアルスローンケタリングキャンサーセンター	ナノ粒子イムノコンジュゲート
KR20170139110A (ko) *	2015-04-21	2017-12-18	애브비 스템센트알엑스 엘엘씨	칼리케아마이신 구성체 및 사용 방법
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
US9708412B2 (en)	2015-05-21	2017-07-18	Harpoon Therapeutics, Inc.	Trispecific binding proteins and methods of use
EP3313527B1 (en)	2015-06-29	2021-02-24	Case Western Reserve University	Anticancer drug-containing plant virus particles
AU2016287585B2 (en)	2015-07-02	2020-12-17	Otsuka Pharmaceutical Co., Ltd.	Lyophilized pharmaceutical compositions
NZ739830A (en)	2015-07-12	2021-12-24	Hangzhou Dac Biotech Co Ltd	Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
EP3322485B1 (en) *	2015-07-16	2020-07-01	Case Western Reserve University	Plant virus particles for delivery of antimitotic agents
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
JP7001585B2 (ja)	2015-09-23	2022-02-04	ファイザー・インク	細胞および細胞培養の方法
WO2017083224A1 (en)	2015-11-09	2017-05-18	Bristol-Myers Squibb Company	Methods to manipulate quality attributes of polypeptides produced in cho cells
IL260289B (en)	2016-01-08	2022-08-01	Bioalliance Cv	Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017172907A1 (en) *	2016-03-29	2017-10-05	Sorrento Therapeutics, Inc.	Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
WO2017175086A1 (en)	2016-04-05	2017-10-12	Pfizer Inc.	Cell culture process
EP3493844A4 (en)	2016-05-20	2021-03-24	Harpoon Therapeutics Inc.	SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
US12599141B2 (en)	2016-06-03	2026-04-14	Case Western Reserve University	Rod-shaped plant viral nanoparticles or virus-like particles for agricultural applications
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor
EP3487527A4 (en)	2016-07-21	2020-03-11	Case Western Reserve University	Plant virus or virus-like particle constructs
US12433840B2 (en)	2016-11-03	2025-10-07	Case Western Reserve University	Melt processed viral nanoparticle constructs
EP3535283A4 (en)	2016-11-03	2020-08-12	Case Western Reserve University	CONSTRUCTIONS OF FUSION TREATED VIRAL NANOPARTICLES
KR20220150408A (ko)	2016-11-14	2022-11-10	항저우 디에이씨 바이오테크 씨오, 엘티디	결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11590183B2 (en)	2017-03-10	2023-02-28	Case Western Reserve University	Cancer immunotherapy using virus particles
WO2018167621A1 (en)	2017-03-16	2018-09-20	Pfizer Inc.	Tyrosine prototrophy
EP3621994A4 (en)	2017-05-12	2020-12-30	Harpoon Therapeutics, Inc.	MESOTHELIN BINDING PROTEINS
WO2018213587A1 (en)	2017-05-17	2018-11-22	Case Western Reserve University	Anticancer trail-targeted plant virus particles
RU2020108580A (ru)	2017-08-03	2021-09-03	Оцука Фармасьютикал Ко., Лтд.	Лекарственное соединение и способы его очистки
JP2020533983A (ja)	2017-09-15	2020-11-26	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
MX2020003915A (es)	2017-10-13	2020-10-08	Harpoon Therapeutics Inc	Proteinas trispecificas y metodos de uso.
US11739301B2 (en)	2017-10-27	2023-08-29	Case Western Reserve University	Tymovirus virus and virus-like particles as nanocarriers for imaging and therapeutic agents
JP7462566B2 (ja)	2018-03-16	2024-04-05	ブリストル－マイヤーズスクイブカンパニー	タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
CN110507824A (zh) *	2018-05-21	2019-11-29	荣昌生物制药（烟台）有限公司	一种抗间皮素抗体及其抗体药物缀合物
PL3710485T3 (pl) *	2018-05-30	2021-09-13	Abbvie Stemcentrx Llc	Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
US10815311B2 (en)	2018-09-25	2020-10-27	Harpoon Therapeutics, Inc.	DLL3 binding proteins and methods of use
JP7699542B2 (ja)	2018-11-20	2025-06-27	コーネルユニバーシティー	放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
EP3891292A1 (en)	2018-12-06	2021-10-13	Pfizer Inc.	Cells with reduced inhibitor production and methods of use thereof
AU2020221271A1 (en) *	2019-02-13	2021-10-07	Coimmune, Inc.	Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
CN113795264A (zh)	2019-03-19	2021-12-14	瓦尔希伯伦私人肿瘤研究基金会	采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
US11390853B2 (en)	2019-04-26	2022-07-19	Case Western Reserve University	Freeze dried viral nanoparticle constructs
US20220288219A1 (en) *	2019-07-08	2022-09-15	Mythic Therapeutics, Inc.	Antigen-binding protein constructs and uses thereof
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US11896676B2 (en)	2019-08-07	2024-02-13	Case Western Reserve University	Targeting cancer cells and tissue using filamentous plant virus particles
US20230071019A1 (en) *	2019-12-04	2023-03-09	The Research Foundation For The State University Of New York	Compositions and methods for reducing off-target toxicity of antibody drug conjugates
US11529430B2 (en)	2019-12-20	2022-12-20	Case Western Reserve University	Polydopamine decorated tobacco mosaic theranostic virus nanoparticles
US12203073B2 (en)	2019-12-20	2025-01-21	Case Western Reserve University	Plant viral RNA delivery nanoparticles and uses thereof
KR20230035576A (ko)	2020-07-07	2023-03-14	비온테크 에스이	Hpv 양성 암 치료용 rna
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
CN112724263B (zh) *	2021-04-02	2021-08-03	上海偌妥生物科技有限公司	改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
CA3225254A1 (en)	2021-07-13	2023-01-19	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
EP4426727A2 (en)	2021-11-03	2024-09-11	Hangzhou Dac Biotech Co., Ltd.	Specific conjugation of an antibody
WO2023148598A1 (en)	2022-02-02	2023-08-10	Pfizer Inc.	Cysteine prototrophy
CN119855620A (zh) *	2022-09-16	2025-04-18	国立研究开发法人量子科学技术研究开发机构	放射性医药组合物的中间体的制造方法、放射性医药组合物的中间体的纯化用试剂盒
EP4608429A1 (en)	2022-10-25	2025-09-03	Peptomyc, S.L.	Combination therapy for the treatment of cancer
JP2026501506A (ja)	2022-12-14	2026-01-16	アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ	Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
WO2024218706A1 (en)	2023-04-21	2024-10-24	Pfizer Inc.	Improved cells and cell cultures
IL324909A (en)	2023-06-07	2026-01-01	Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron	Combination therapy with mek inhibitors for the treatment of cancer
IL325025A (en)	2023-06-07	2026-01-01	Fundaci? Privada Inst Dinvestigaci? Oncol?Gica De Vall Hebron	Combination therapy with BRAF inhibitors for cancer treatment
EP4473974A1 (en)	2023-06-07	2024-12-11	Peptomyc, S.L.	Omomyc and kras inhibitors combination therapy for the treatment of cancer
KR20250043317A (ko) *	2023-09-21	2025-03-28	주식회사 피노바이오	운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
WO2026033885A1 (en)	2024-08-08	2026-02-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
TW202541837A (zh)	2023-12-08	2025-11-01	日商安斯泰來製藥公司	含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4671958A (en)	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US4970198A (en)	1985-10-17	1990-11-13	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) *	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4771128A (en) *	1986-10-10	1988-09-13	Cetus Corporation	Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5079233A (en)	1987-01-30	1992-01-07	American Cyanamid Company	N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5037651A (en)	1987-01-30	1991-08-06	American Cyanamid Company	Dihydro derivatives of LL-E33288 antibiotics
US5053394A (en)	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5134075A (en) *	1989-02-17	1992-07-28	Oncogen Limited Partnership	Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DK0489149T3 (da)	1990-06-27	2001-12-27	Univ Princeton	Prober til påvisning af mutant P53
CA2082160C (en) *	1991-03-06	2003-05-06	Mary M. Bendig	Humanised and chimeric monoclonal antibodies
US5714350A (en) *	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) *	1992-06-17	1997-11-11	Board Of Regents, The University Of Texas	Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5484892A (en) *	1993-05-21	1996-01-16	Dana-Farber Cancer Institute, Inc.	Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
US5436265A (en) *	1993-11-12	1995-07-25	Merck Frosst Canada, Inc.	1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5712474A (en) *	1993-09-29	1998-01-27	Canon Kabushiki Kaisha	Image processing apparatus for correcting blurring of an image photographed by a video camera
US6310185B1 (en)	1994-03-08	2001-10-30	Memorial Sloan Kettering Cancer Center	Recombinant human anti-Lewis Y antibodies
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ATE201445T1 (de)	1994-08-12	2001-06-15	Myriad Genetics Inc	Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
DE69534530T2 (de) *	1994-08-12	2006-07-06	Immunomedics, Inc.	Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) *	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) *	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US7147851B1 (en) *	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) *	1996-11-01	2002-10-03	Smithkline Beecham Corporation	Anti-RSV human monoclonal antibodies
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
US7541034B1 (en) *	1997-03-20	2009-06-02	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6306393B1 (en) *	1997-03-24	2001-10-23	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) *	1997-03-24	2001-02-06	Immunomedics, Inc.	Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2635352C (en) *	1997-06-13	2012-09-11	Genentech, Inc.	Stabilized antibody formulation
AT408613B (de) *	1998-06-17	2002-01-25	Immuno Ag	Pharmazeutisches faktor vii-präparat
US6183477B1 (en) *	1998-09-04	2001-02-06	Smith & Nephew, Inc.	Attachment tool for drill guide
KR100345463B1 (ko) *	1998-11-19	2003-01-08	주)녹십자	B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
JP2000226336A (ja) *	1998-11-30	2000-08-15	Sankyo Co Ltd	免疫グロブリン製剤
DK1137941T4 (da)	1998-12-10	2014-01-06	Brystol Myers Squibb Company	Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
DE60042785D1 (de) *	1999-06-09	2009-10-01	Immunomedics Inc	Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
DE60009926T2 (de) *	1999-08-17	2005-04-07	Novo Nordisk Health Care Ag	Stabilisierung von gefriergetrocknetem kuchen
SI1232392T1 (en) *	1999-10-12	2003-10-31	Connex Gesellschaft Zur Optimierung Von Forschung Und	Improved method for the detection of acid resistant bacteria of the genus helicobacter in stool
US20010046496A1 (en) *	2000-04-14	2001-11-29	Brettman Lee R.	Method of administering an antibody
GB0013810D0 (en) *	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
GB0210121D0 (en) *	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
SG187991A1 (en) *	2002-05-02	2013-03-28	Wyeth Corp	Calicheamicin derivative-carrier conjugates

2003
- 2003-05-02 SG SG2011035912A patent/SG187991A1/en unknown
- 2003-05-02 SI SI200332437T patent/SI2371392T1/sl unknown
- 2003-05-02 ES ES16180729T patent/ES2916174T3/es not_active Expired - Lifetime
- 2003-05-02 CA CA002483552A patent/CA2483552A1/en not_active Abandoned
- 2003-05-02 PT PT161807292T patent/PT3127553T/pt unknown
- 2003-05-02 BR BR122019027966A patent/BR122019027966B8/pt not_active IP Right Cessation
- 2003-05-02 NZ NZ573563A patent/NZ573563A/en not_active IP Right Cessation
- 2003-05-02 CA CA2871117A patent/CA2871117A1/en not_active Abandoned
- 2003-05-02 RU RU2004135101A patent/RU2422157C3/ru active Protection Beyond IP Right Term
- 2003-05-02 LT LTEP16180729.2T patent/LT3127553T/lt unknown
- 2003-05-02 PL PL410219A patent/PL224150B1/pl unknown
- 2003-05-02 WO PCT/US2003/013910 patent/WO2003092623A2/en not_active Ceased
- 2003-05-02 UA UA20041209865A patent/UA88599C2/ru unknown
- 2003-05-02 SI SI200332489A patent/SI1507556T1/sl unknown
- 2003-05-02 EP EP03724432.4A patent/EP1507556B1/en not_active Expired - Lifetime
- 2003-05-02 PL PL374523A patent/PL222725B1/pl unknown
- 2003-05-02 LT LTEP03724432.4T patent/LT1507556T/lt unknown
- 2003-05-02 SI SI200332621T patent/SI3127553T1/sl unknown
- 2003-05-02 NZ NZ586071A patent/NZ586071A/en not_active IP Right Cessation
- 2003-05-02 HU HUE03724432A patent/HUE030806T2/hu unknown
- 2003-05-02 PT PT37244324T patent/PT1507556T/pt unknown
- 2003-05-02 HU HUE11157981A patent/HUE027590T2/hu unknown
- 2003-05-02 ES ES03724432.4T patent/ES2593304T3/es not_active Expired - Lifetime
- 2003-05-02 EP EP16180729.2A patent/EP3127553B1/en not_active Expired - Lifetime
- 2003-05-02 KR KR1020117009631A patent/KR101125524B1/ko not_active Expired - Lifetime
- 2003-05-02 BR BR122019027974-8A patent/BR122019027974B1/pt not_active IP Right Cessation
- 2003-05-02 JP JP2004500808A patent/JP5153057B2/ja not_active Expired - Lifetime
- 2003-05-02 AU AU2003231293A patent/AU2003231293A1/en not_active Abandoned
- 2003-05-02 PL PL411824A patent/PL224844B1/pl unknown
- 2003-05-02 HU HUE16180729A patent/HUE057124T2/hu unknown
- 2003-05-02 TW TW092112147A patent/TWI379693B/zh not_active IP Right Cessation
- 2003-05-02 DK DK16180729.2T patent/DK3127553T3/da active
- 2003-05-02 PT PT111579819T patent/PT2371392E/pt unknown
- 2003-05-02 MX MXPA04010792A patent/MXPA04010792A/es active IP Right Grant
- 2003-05-02 SG SG10201700289RA patent/SG10201700289RA/en unknown
- 2003-05-02 EP EP11157981.9A patent/EP2371392B1/en not_active Expired - Lifetime
- 2003-05-02 DK DK11157981.9T patent/DK2371392T3/en active
- 2003-05-02 CN CNB038152606A patent/CN100482277C/zh not_active Expired - Lifetime
- 2003-05-02 TW TW101100850A patent/TWI438010B/zh not_active IP Right Cessation
- 2003-05-02 DK DK03724432.4T patent/DK1507556T3/en active
- 2003-05-02 US US10/428,894 patent/US8153768B2/en active Active
- 2003-05-02 SG SG200607459-5A patent/SG165158A1/en unknown
- 2003-05-02 BR BRPI0309868A patent/BRPI0309868B8/pt not_active IP Right Cessation
- 2003-05-02 ES ES11157981.9T patent/ES2545745T3/es not_active Expired - Lifetime
- 2003-05-02 KR KR1020047017670A patent/KR101062628B1/ko not_active Expired - Lifetime
- 2003-05-02 PL PL413302A patent/PL228741B1/pl unknown
- 2003-05-02 PL PL410218A patent/PL224001B1/pl unknown
- 2003-11-03 US US10/699,874 patent/US8747857B2/en active Active
2004
- 2004-10-28 NO NO20044663A patent/NO339730B1/no not_active IP Right Cessation
- 2004-10-28 CR CR7557A patent/CR7557A/es not_active Application Discontinuation
- 2004-11-01 IL IL164946A patent/IL164946A/en active Protection Beyond IP Right Term
- 2004-11-22 EC EC2004005445A patent/ECSP045445A/es unknown
- 2004-12-01 ZA ZA200409752A patent/ZA200409752B/xx unknown
2009
- 2009-06-26 AU AU2009202609A patent/AU2009202609B2/en active Active
2010
- 2010-05-31 ZA ZA2010/03874A patent/ZA201003874B/en unknown
2011
- 2011-03-09 RU RU2011108928A patent/RU2602878C3/ru active Protection Beyond IP Right Term
- 2011-09-29 JP JP2011215042A patent/JP5441971B2/ja not_active Expired - Lifetime
2012
- 2012-02-13 US US13/372,172 patent/US8835611B2/en not_active Expired - Lifetime
- 2012-07-02 CR CR20120364A patent/CR20120364A/es unknown
2013
- 2013-03-26 JP JP2013064065A patent/JP5756489B2/ja not_active Expired - Lifetime
- 2013-06-06 PH PH12013501158A patent/PH12013501158A1/en unknown
- 2013-06-06 PH PH12013501159A patent/PH12013501159A1/en unknown
- 2013-08-09 CR CR20130390A patent/CR20130390A/es unknown
2014
- 2014-01-26 IL IL230659A patent/IL230659A/en active IP Right Grant
- 2014-03-07 US US14/201,184 patent/US9351986B2/en not_active Expired - Fee Related
- 2014-12-18 JP JP2014256667A patent/JP2015061875A/ja active Pending
2015
- 2015-08-21 CY CY20151100732T patent/CY1116634T1/el unknown
2016
- 2016-05-03 US US15/145,238 patent/US20160303252A1/en not_active Abandoned
- 2016-09-05 CY CY20161100872T patent/CY1117973T1/el unknown
- 2016-09-08 NO NO20161431A patent/NO344509B1/no not_active IP Right Cessation
- 2016-10-24 RU RU2016141576A patent/RU2678818C2/ru active
2017
- 2017-01-26 JP JP2017011948A patent/JP6872376B2/ja not_active Expired - Lifetime
- 2017-10-25 HU HUS1700038C patent/HUS1700038I1/hu unknown
- 2017-10-25 LU LU00044C patent/LUC00044I2/fr unknown
- 2017-10-31 NL NL300903C patent/NL300903I2/nl unknown
- 2017-11-03 CY CY2017035C patent/CY2017035I1/el unknown
- 2017-11-08 LT LTPA2017036C patent/LTC2371392I2/lt unknown
- 2017-11-16 BE BE2017C049C patent/BE2017C049I2/fr unknown
- 2017-11-21 NO NO2017061C patent/NO2017061I1/no unknown
- 2017-11-30 FR FR17C1054C patent/FR17C1054I2/fr active Active
2018
- 2018-07-30 US US16/048,511 patent/US20180339058A1/en not_active Abandoned
2022
- 2022-01-14 CY CY20221100035T patent/CY1124900T1/el unknown

Also Published As

Publication number	Publication date
JP6872376B2 (ja)	2021-05-19
PL224150B1 (pl)	2016-11-30
CR20130390A (es)	2013-11-08
RU2016141576A (ru)	2018-05-03
CA2871117A1 (en)	2003-11-13
NZ573563A (en)	2010-10-29
IL230659A (en)	2016-02-29
ES2593304T3 (es)	2016-12-07
PL413302A1 (pl)	2016-05-23
NO20161431A1 (no)	2005-01-25
BRPI0309868B1 (pt)	2020-04-28
EP2371392B1 (en)	2015-07-08
BR122019027966B8 (pt)	2021-07-27
BR122019027974B1 (pt)	2022-06-14
ES2545745T3 (es)	2015-09-15
KR20110050753A (ko)	2011-05-16
TW200404005A (en)	2004-03-16
US8747857B2 (en)	2014-06-10
US20040082764A1 (en)	2004-04-29
US20120213804A1 (en)	2012-08-23
PL411824A1 (pl)	2015-08-17
US20160303252A1 (en)	2016-10-20
DK2371392T3 (en)	2015-08-31
TWI379693B (en)	2012-12-21
CR7557A (es)	2008-10-03
AU2003231293A1 (en)	2003-11-17
JP5153057B2 (ja)	2013-02-27
NO339730B1 (no)	2017-01-23
US8153768B2 (en)	2012-04-10
NO20044663L (no)	2005-01-25
US20040192900A1 (en)	2004-09-30
DK1507556T3 (en)	2016-09-12
JP5756489B2 (ja)	2015-07-29
PT1507556T (pt)	2016-09-28
WO2003092623A3 (en)	2004-03-18
WO2003092623A2 (en)	2003-11-13
PH12013501159B1 (en)	2015-12-02
KR101062628B1 (ko)	2011-09-07
PT2371392E (pt)	2015-10-07
US20140235835A1 (en)	2014-08-21
RU2011108928A (ru)	2012-09-20
RU2602878C3 (ru)	2021-11-24
CY2017035I2 (el)	2018-04-04
JP2017105801A (ja)	2017-06-15
CN1665532A (zh)	2005-09-07
DK3127553T3 (da)	2022-01-31
FR17C1054I1 (2)	2018-01-12
HUS1700038I1 (hu)	2017-11-28
US8835611B2 (en)	2014-09-16
HK1070825A1 (en)	2005-06-30
NO2017061I1 (no)	2017-11-21
CY1124900T1 (el)	2023-01-05
CY2017035I1 (el)	2018-04-04
LUC00044I2 (2)	2018-02-26
RU2678818C2 (ru)	2019-02-04
TWI438010B (zh)	2014-05-21
JP2013163678A (ja)	2013-08-22
SG165158A1 (en)	2010-10-28
UA88599C2 (ru)	2009-11-10
TW201231089A (en)	2012-08-01
PL228741B1 (pl)	2018-05-30
AU2009202609B2 (en)	2012-07-26
LTC2371392I2 (lt)	2019-03-25
KR101125524B1 (ko)	2012-03-22
LUC00044I1 (2)	2017-11-03
RU2602878C2 (ru)	2016-11-20
LTPA2017036I1 (lt)	2017-11-27
IL164946A (en)	2015-06-30
NZ586071A (en)	2012-02-24
HUE057124T2 (hu)	2022-04-28
CY1116634T1 (el)	2017-03-15
PH12013501159A1 (en)	2015-12-02
PH12013501158B1 (en)	2015-11-09
EP3127553B1 (en)	2021-12-01
ES2916174T3 (es)	2022-06-28
HUE030806T2 (hu)	2017-05-29
HUE057124T4 (hu)	2022-02-28
AU2009202609A1 (en)	2009-07-16
SG10201700289RA (en)	2017-02-27
PL222725B1 (pl)	2016-08-31
PH12013501158A1 (en)	2015-11-09
SI2371392T1 (sl)	2015-10-30
RU2422157C3 (ru)	2021-04-23
JP5441971B2 (ja)	2014-03-12
CA2483552A1 (en)	2003-11-13
FR17C1054I2 (fr)	2019-01-11
SI3127553T1 (sl)	2022-02-28
NL300903I2 (nl)	2018-02-08
SI1507556T1 (sl)	2016-10-28
ECSP045445A (es)	2005-01-28
IL164946A0 (en)	2005-12-18
ZA200409752B (en)	2010-08-25
CR20120364A (es)	2012-10-05
PL224001B1 (pl)	2016-11-30
PL224844B1 (pl)	2017-02-28
MXPA04010792A (es)	2005-03-07
IL230659A0 (en)	2014-03-31
NO344509B1 (no)	2020-01-20
LT3127553T (lt)	2022-04-11
JP2012051900A (ja)	2012-03-15
BRPI0309868B8 (pt)	2021-05-25
US9351986B2 (en)	2016-05-31
SG187991A1 (en)	2013-03-28
BE2017C049I2 (2)	2022-08-09
KR20050006220A (ko)	2005-01-15
PL410219A1 (pl)	2015-03-30
EP1507556A2 (en)	2005-02-23
JP2015061875A (ja)	2015-04-02
EP3127553A1 (en)	2017-02-08
LT1507556T (lt)	2016-10-10
HK1162926A1 (en)	2012-09-07
JP2005524700A (ja)	2005-08-18
HUE027590T2 (hu)	2016-11-28
ZA201003874B (en)	2019-12-18
EP1507556A4 (en)	2009-01-07
PL410218A1 (pl)	2015-03-30
BR122019027966B1 (pt)	2020-11-17
PL374523A1 (pl)	2005-10-31
US20180339058A1 (en)	2018-11-29
RU2004135101A (ru)	2005-06-27
CN100482277C (zh)	2009-04-29
RU2016141576A3 (2)	2018-05-03
CY1117973T1 (el)	2017-05-17
EP1507556B1 (en)	2016-07-27
EP2371392A1 (en)	2011-10-05
BR0309868A (pt)	2005-10-18
RU2422157C2 (ru)	2011-06-27

Publication	Publication Date	Title
PT3127553T (pt)	2022-01-24	Conjugados de derivado da caliqueamicina - transportador
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
DK1556385T3 (da)	2010-06-14	Heterocyclocarboxamid-derivater
DE60330372D1 (de)	2010-01-14	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
ATE438644T1 (de)	2009-08-15	Chinazolinderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður
DK1474408T3 (da)	2012-06-25	N-Phenyl-2-pyrimidinaminderivater
DK2042504T3 (da)	2011-09-19	Kondenseret azole-pyrimidin-derivat
DK1594840T3 (da)	2007-02-05	Piperidin-benzensulfonamid-derivater
EP1557594A4 (en)	2006-01-18	OIL RING
ATE352550T1 (de)	2007-02-15	Chinazolinderivate
ATE420066T1 (de)	2009-01-15	Amidoacetonitrilderivate
DK1606277T3 (da)	2008-08-18	Imidazol-4-yl-ethynyl-pyridinderivater
ATE454381T1 (de)	2010-01-15	Benzofuranderivat
DE60307512D1 (de)	2006-09-21	3h-chinazoline -4-on derivaten
ATE354365T1 (de)	2007-03-15	N-thiazol-2-yl-benzamid-derivate
ATE423771T1 (de)	2009-03-15	Tetrahydrochinolinderivate
ATE457299T1 (de)	2010-02-15	4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DK1706373T3 (da)	2010-01-18	Amidoacetonitrilderivater
BR0311793B1 (pt)	2013-12-31	Projétil de neblina
IS8045A (is)	2005-09-26	Púrín-6-ón-afleiður
DE50306277D1 (de)	2007-02-22	4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
EP1405844A4 (en)	2006-09-20	CYCLOALKENONDERIVAT
ITMI20030948A1 (it)	2003-11-14	Portalampada